denileukin diftitox-cxdl

FDA Drug Profile — LYMPHIR

Drug Details

Generic Name
denileukin diftitox-cxdl
Brand Names
LYMPHIR
Application Number
BLA761312
Sponsor
Citius Pharmaceuticals, Inc.
NDC Codes
1
Dosage Forms
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Routes
INTRAVENOUS
Active Ingredients
DENILEUKIN DIFTITOX

Indications and Usage

1 INDICATIONS AND USAGE LYMPHIR is indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. LYMPHIR is an IL2-receptor-directed cytotoxin indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. ( 1 )